You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Polaris Oncology Survivor Transition POST System

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: 100

    DESCRIPTION provided by applicant By January oncology care providers will be expected to craft Survivorship Care Plans SCPs for all individuals ending active treatment for cancer however there is a lack of systematic study of the impact survivorship planning has on patients providers or healthcare systems The Polaris Oncology Survivorship Transition POST program is a web based sy ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a novel method for inhibiting diabetic retinopathy

    SBC: CMP Tarnhelm Partners            Topic: N

    DESCRIPTION provided by applicant The long term objective of this project study is to develop a monoclonal antibody that inhibits the progression of diabetic retinopathy Insulin like growth factor I IGF I has been implicated in both endothelial dysfunction as well as the proliferative phase of the disease but IGF I concentrations in retina are not increased During hyperglycemia IGF I activa ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Remote Brief Intervention and Referral to Treatment Service for Alcohol (R-BIRT)

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NIAAA

    DESCRIPTIONprovided by applicantSignificanceThe USPHSTFSAMHSACDCand NIAAA have affirmed the importance of screening in medical settings for alcohol consumption that exceeds the NIAAA low risk limitsbrief educational and motivational counseling for those who screen positive or have other evidence of an Alcohol Use Disorderandwhen appropriatereferral to treatmentSBIRTHowevertranslation to clinical p ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma

    SBC: Annias Immunotherapeutics, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Malignant primary brain tumors represent the most frequent cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma Glioblastoma GBM is uniformly lethal and current therapy is non specific and produces a median overall survival of andlt months In contrast immunotherapeutic approaches are exq ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Medical Images HTML and Clinical Trial Remote Collaboration

    SBC: HEART IMAGING TECHNOLOGIES, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Medical drugs and devices are regulated by the U S Food and Drug Administration FDA based on data from multicenter clinical trials In U S spending on clinical trials was approximately $ billion Over the past decade the efficiency of clinical trials has been improved by electronic data capture EDC systems whose use has increased from to ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Stroke Treatment by Chemically-induced Hypothermia

    SBC: JT Pharmaceuticals, Inc.            Topic: 101

    DESCRIPTION provided by applicant Stroke is a leading cause of human death and disability in the United States while clinical therapy for acute stroke is limited and unsatisfactoy The many failures in clinical trials strongly endorse the idea that to battle this multifaceted bran disorder novel strategies that target multiple cell types and different mechanisms are needed to achieve therapeut ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Developing Intravesical Liposomes for Interstitial Cystitis

    SBC: LIPELLA PHARMACEUTICALS INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. (Pittsburgh, PA) is a clinical-stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions. Lipella is submitting a research proposal to the Small Business Technology Transfer program titled Developing Intravesical Liposomes for Interstitial Cystitis . The project proposes to evaluate the sa ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re

    SBC: Apogee Biotechnology Corporation            Topic: 102

    DESCRIPTION provided by applicant Diffuse large B cell lymphoma DLBCL represents one of the most common variants of Non Hodgkinandapos s lymphoma NHL and oncogenic herpesviruses EBV and KSHV are the etiologic agents for the majority of these tumors in patients over or those infected with the human immunodeficiency virus HIV Despite modest improvements in outcomes for patients rece ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Developing Intravesical Liposomes for Interstitial Cystitis

    SBC: LIPELLA PHARMACEUTICALS INC.            Topic: NIDDK

    DESCRIPTION provided by applicant Lipella Pharmaceuticals Inc Pittsburgh PA is a clinical stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions Lipella is submitting a research proposal to the Small Business Technology Transfer program titled andquot Developing Intravesical Liposomes for Interstitial Cystitisandquot The project proposes to e ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD, LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government